CMRX - EU drug regulator begins review of Bavarian Nordic's smallpox vaccine for monkeypox

A panel of the European Medicines Agency (EMA) started a review to extend the use of Bavarian Nordic's (OTCPK:BVNKF) (OTCPK:BVNRY) smallpox vaccine Imvanex for protecting against monkeypox, amid the rising cases in Europe. Bavarian's smallpox vaccine MVA-BN is sold as Imvanex in Europe, as Jynneos in the U.S., and under the name Imvamune in Canada. The vaccine is already approved for use against monkeypox in the U.S. and Canada. The EMA said Imvanex is also considered a potential vaccine for monkeypox because of the similarity between the monkeypox and smallpox viruses. The EMA added that the decision to start the review by the Committee for Medicinal Products for Human Use is based on results from non-clinical data suggesting that the vaccine triggers antibodies which target the monkeypox virus. The EMA said that due to limited availability of Imvanex, its Emergency Task Force (ETF) recommended that Jynneos can be used against monkeypox in the EU and

For further details see:

EU drug regulator begins review of Bavarian Nordic's smallpox vaccine for monkeypox